Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 121

Sort by

Sort Order Select

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

Preclinical Characterization of Prgn-3006 Ultracar-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer

Tim Chan, PhD, Xiaohong Ma, Fernando Carvajal-Borda, DVM, Jose Velez, Jacques Plummer, Lindsey Shepard, Rutul R Shah, David A Sallman, MD, Helen Sabzevari, PhD

Blood (2019) 134 (Supplement_1): 2660.

https://doi.org/10.1182/blood-2019-130617

Published: 2019

Journal Articles

Thrombotic Risk Assessment in a Prospective Cohort of Newly Diagnosed Ambulatory Cancer Patients Candidate to Chemotherapy

Blood (2019) 134 (Supplement_1): 3642.

https://doi.org/10.1182/blood-2019-129901

Published: 2019

Journal Articles

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Paul G. Richardson, MD, Alessandra Larocca, Xavier Leleu, MD PhD, Albert Oriol, MD, Agne Paner, MD, Paula Rodriguez Otero, Cyrille Touzeau, MD, Adrián Alegre Amor, MD, Christopher Maisel, MD, María-Victoria Mateos, MD PhD, Amitabha Mazumder, MD, Peter Strang, MD, Oskar Öhman, MSc, Johan Harmenberg, MD PhD, Stojan Zavisic, Joan Bladé, MD

Blood (2019) 134 (Supplement_1): 3487.

https://doi.org/10.1182/blood-2019-124832

Published: 2019

Journal Articles

Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging

Christian M. Schuerch, MD PhD, Darci J. Phillips, MD PhD, Salil S. Bhate, MMath, Graham L. Barlow, BA, Steven P Fling, PhD, Nirasha Ramchurren, Robert Pierce, MD, Martin A Cheever, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Garry P. Nolan, PhD

Blood (2019) 134 (Supplement_1): 1521.

https://doi.org/10.1182/blood-2019-125315

Published: 2019

Journal Articles

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Hind Al Azzawi, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 1379.

https://doi.org/10.1182/blood-2019-131348

Published: 2019

Journal Articles

Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma

Yixin Yao, PhD, Yang Liu, MD, Hui Zhang, Angela Leeming, Joseph Mitchell McIntosh, Preetesh Jain, MBBS,MDDM,PhD, Liang Zhang, MD PhD, Krystle Nomie, PhD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 1506.

https://doi.org/10.1182/blood-2019-126738

Published: 2019

Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD

Blood (2018) 132 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2018-99-115680

Published: 2018

Journal Articles

Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)

Jeffrey I. Zwicker, MD, Benjamin L. Schlechter, MD, Jack Davis Stopa, PhD, Howard A. Liebman, MD, Anita Aggarwal, PhDDO, Thomas Caughey, MD, Ken A. Bauer, MD, Nancy Kuemmerle, D.O., Ellice Y. Wong, MD, Ted Wun, MD, Marilyn Mclaughlin, MD, Maneka Puligandla, MS, Donna S Neuberg, ScD, Bruce Furie, MD, Robert C. Flaumenhaft, MD PhD

Blood (2018) 132 (Supplement 1): 985.

https://doi.org/10.1182/blood-2018-99-114946

Published: 2018

Journal Articles

Neutrophil Extracellular Traps Enhance Procoagulant Activity in Patients with Oral Squamous Cell Carcinoma

Baorong Li, MD, Yingmiao Liu, MD, Cong Zhang, MD, Yan Kou, MD, Lili Zou, MD, Hui Liang, MD, Li Hou, MD, Tao Li, MD, Yan Zhang, MD, Nan Zuo, MD, Wenhui Liu, MD, Jialan Shi, MD PhD, Tenglong Hu, MD PhD

Blood (2018) 132 (Supplement 1): 2399.

https://doi.org/10.1182/blood-2018-99-115737

Published: 2018

Journal Articles

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, Stacey L. Fanning, PhD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, Michael B Atkins, MD, Scott D. Rowley, MD, Noa Biran, MD, David S Siegel, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2018-99-120240

Published: 2018

Journal Articles

Folate Testing and Deficiency in Hospitalized Cancer Patients

Zachary D. Epstein-Peterson, MD, Gerald A. Soff, MD, Maly Fenelus, MD, Deborah Korenstein, MD

Blood (2018) 132 (Supplement 1): 5814.

https://doi.org/10.1182/blood-2018-99-117073

Published: 2018

Journal Articles

Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector

Atin Jindal, MD, Jan Kover, BPharm, Vanja Raduka, PharmD, R.Ph, Timothy E. O'Brien, MD

Blood (2018) 132 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2018-99-114282

Published: 2018

Journal Articles

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Carlo Gambacorti-Passerini, MD, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang-Ju Wu, MD, PhD, Jolanda Paolini, Sherry Li, Tae Min Kim

Blood (2017) 130 (Supplement 1): 4128.

https://doi.org/10.1182/blood.V130.Suppl_1.4128.4128

Published: 2017

Journal Articles

Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma

Joshua R Richter, MD, Noa Biran, MD, Dhakshila Paramanathan, Srikesh Arunajadai, PhD, Victoria DeVincenzo, Ruth Pe Benito, Brooke Gruman, Sukhi Kaur, John Hervey, Eric Schultz, Scott Paddock, Andrew L. Pecora, MD, David H. Vesole, MD, David Siegel, MD PhD, Stuart L. Goldberg, MD

Blood (2017) 130 (Supplement 1): 679.

https://doi.org/10.1182/blood.V130.Suppl_1.679.679

Published: 2017

Journal Articles

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

Dante Descalzi-Montoya, PhD, Kira Goldgirsh, MS, Zheng Yang, MS, Eugenia Dziopa, MS, Iriana Colorado, MS, Rena Feinman, PhD, Themba Nyirenda, PhD, David H. Vesole, MD, Pashna N. Munshi, MD, Scott D. Rowley, MD, Noa Biran, MD, Joshua R Richter, MD, David Siegel, MD PhD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2017) 130 (Supplement 1): 1862.

https://doi.org/10.1182/blood.V130.Suppl_1.1862.1862

Published: 2017

Journal Articles

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

Andres Forero-Torres, MD, Seth Rosen, MD, David C. Smith, MD, Glenn Lesser, MD, Julio Peguero, MD, Shilpa Gupta, MD, Justin M. Watts, MD, Marcus Noel, MD, Razelle Kurzrock, MD, Haeseong Park, MD, Patricia LoRusso, DO, Catherine C. Coombs, MD, Fred Zheng, MD, Julie Switzky, RN, Swamy Yeleswaram, PhD, Gerald Falchook, MD

Blood (2017) 130 (Supplement 1): 4048.

https://doi.org/10.1182/blood.V130.Suppl_1.4048.4048

Published: 2017

Journal Articles

Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly

Nancy K Gillis, PharmD, Markus Ball, PhD, Qing Zhang, MD, YuLong Zhao, PhD, Sean Yoder, M.S, Maria E. Balasis, Tania E. Mesa, David Sallman, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Alan F List, MD, Howard L McLeod, PharmD, Dana E Rollison, PhD, Eric Padron, MD

Blood (2016) 128 (22): 295.

https://doi.org/10.1182/blood.V128.22.295.295

Published: 2016

Journal Articles

Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

Melissa A. Fischer, PhD, Sharon Friedlander, PhD, Leah Hogdal, PhD, Pia Arrate, Hua Chang, PhD, Trinayan Kashyap, MS, Christian Argueta, PhD, Boris Klebanov, MA, MS, William Senapedis, PhD, Erkan Baloglu, PhD MBA, Margaret S. Lee, PhD, Sharon Shacham, PhD MBA, Michael R. Savona, MD

Blood (2016) 128 (22): 3949.

https://doi.org/10.1182/blood.V128.22.3949.3949

Published: 2016

Journal Articles

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

Varun V Prabhu, PhD, Amriti Lulla, Christina L Kline, PhD, Peter J Van den Heuvel, PhD, Mala K. Talekar, MD, Jessica M Wagner, Rohinton S Tarapore, PhD, David T Dicker, Mathew J Garnett, PhD, Ultan McDermott, MD PhD, Cyril H Benes, PhD, Jeffrey J. Pu, MD PhD, David F. Claxton, MD, Wolfgang Oster, MD PhD, Joshua E Allen, PhD, Wafik S. El-Deiry, MD PhD

Blood (2016) 128 (22): 2759.

https://doi.org/10.1182/blood.V128.22.2759.2759

Published: 2016

NARROW

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Preclinical Characterization of Prgn-3006 Ultracar-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer

Thrombotic Risk Assessment in a Prospective Cohort of Newly Diagnosed Ambulatory Cancer Patients Candidate to Chemotherapy

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)

Neutrophil Extracellular Traps Enhance Procoagulant Activity in Patients with Oral Squamous Cell Carcinoma

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Folate Testing and Deficiency in Hospitalized Cancer Patients

Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly

Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only